01 — At a Glance
India’s Most Aggressive Diagnostic Chain Is Running Out of Oxygen
- 52-Week High / Low₹1,180 / ₹800
- FY25 Annual Revenue₹681 Cr
- FY25 PAT₹144 Cr
- Q3 FY26 Revenue₹205 Cr
- Q3 FY26 EPS₹4.20
- Book Value₹84.2
- Price to Book11.0x
- Debt / Equity0.42x
- Operating Margin40.4%
- 6-Month Return-10.6%
The Auditor’s Opening Note: Vijaya closed Q3 with ₹205 crore revenue (+21.4% YoY), ₹43.2 crore PAT (+22.8% YoY), 41.9% EBITDA margin, and simultaneously lost its CFO, merged Medinova via amalgamation, and is still trading at the richest P/E multiple in its peer set. The 6-month return is -10.6%, meaning the stock has punished excellence. Apparently, India’s retail investor prefers mediocrity with a side of stability.
02 — Introduction
Welcome to the Diagnostic Wars: Where Everyone’s Getting Scanned and Prices Keep Exploding
Vijaya Diagnostic is that rare Indian business which walks like a disruptor, quacks like a disruptor, but makes money like a utility. 70% of its revenue comes from Hyderabad. It has 81 diagnostic centers and 11 reference laboratories scattered across South India. It’s one of the first diagnostic chains in India to offer PET-CT scans. And it’s expanding aggressively into West Bengal, Pune, and Bangalore like it’s printing licenses.
But here’s the thing: a P/E of 59.7x in a mid-cap diagnostic chain is not what your portfolio manager writes home about. Your portfolio manager calls it a “secular growth story with margin tailwinds,” then quietly buys it for their wife’s DP account at ₹750.
Q3 FY26 delivered the highest-ever quarterly revenue: ₹205 crore. That’s +21.4% YoY. Tests conducted hit 14.79 million annually (FY25). Revenue per test is ₹487. Revenue per footfall is ₹1,756. The wellness segment has climbed from 8% pre-COVID to 15% now and management says it’s heading “north of 20%.” Simultaneously, the company merged its Medinova subsidiary via an NCLT-approved scheme, appointed a new CFO mid-quarter, and is still guiding 40% EBITDA margins despite all this institutional turbulence.
Let’s break down whether you’re paying ₹931 for a diagnostic machine… or just paying.
Management’s Own Words (Concall Feb 2026): “Highest ever quarterly revenue in nearly two decades.” When your biggest achievement is a quarterly record in a business you’ve run for decades, you either need better hype or better strategy. Preferably both.
03 — Business Model: The Hub-Spoke Playbook That Everyone Copies But Nobody Perfects
Scan Your Blood. Wait 4 Hours. Celebrate the Lack of Chaos.
Vijaya’s business is brutally simple. A patient walks in, gets tested (pathology + radiology), and waits for results. Pathology (61% of revenue) is straightforward: blood, urine, and stool tests. Radiology (39% of revenue) is the moat: MRI, CT, PET-CT, and the high-end kit that requires trained radiologists to explain why you need a second opinion.
The “hub-and-spoke” model is just a fancy way of saying: “We have one big lab in Hyderabad (the hub) and smaller collection points everywhere else (the spokes).” Tests get collected at spokes, shipped to the hub, analyzed, and results come back. Hubs break even in 12–14 months. Spokes break even in 2–3 quarters. Mature hubs do ₹110 crore+ revenue annually. Mature spokes do ₹25–40 crore. It’s not rocket science; it’s plumbing science.
What Vijaya does differently: It merged Medinova (Pune’s largest B2C diagnostic chain) in Nov 2025, effectively acquiring Pune’s market leadership without paying full acquisition price. It’s ramping new hubs in West Bengal faster than expected. And it’s started playing the “wellness” game hard—preventive health checkups that are now 15% of revenue and growing faster than the core diagnostic business.
B2C Revenue92%Consumer Direct
Radiology Share37%Of Revenue
Wellness Segment15%Rising to 20%+
Tests Per Footfall3.53FY25 Average
Market Share Note: Vijaya commands 70% market share in Hyderabad. That’s not leadership—that’s monopoly with training wheels. In Rest of AP/Telangana it’s 19%. In Pune (post-Medinova), it’s probably the #1 integrated chain. But P/E at 59.7x means the market is already pricing in a future where Vijaya becomes a national diagnostic giant. Question: Is that future real, or just an investor’s fever dream?
💬 Drop a question: Do you think wellness diagnostics can sustain 20%+ revenue mix, or will it plateau as a novelty?
04 — Financials Overview
Q3 FY26: When Your Best Quarter Looks Like Your Worst Trading Day
Continue reading with a premium membership.
